Advertisement

Therapie von Aszites und Nierenversagen bei Leberzirrhose

  • J. Schölmerich
Chapter

Zusammenfassung

Der Begriff Aszites bezeichnet die Ansammlung von Flüssigkeit in der freien Bauchhöhle. Aszites kann bei verschiedenen Erkrankungen auftreten; seine Ätiologie und Pathogenese sind nicht einheitlich. In der Regel ist ein Aszites das Symptom einer weit fortgeschrittenen Erkrankung und weist auf eine schlechte Prognose hin. Da die Therapie somit in den meisten Fällen palliativer Natur ist, sollten sich alle Maßnahmen zur Diagnostik und Therapie diesem Gesichtspunkt unterordnen.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Bard C, Lafortune M, Breton G (1986) Ascites: ultrasound guidance or blind paracentesis? Can Med Assoc J135: 209–210Google Scholar
  2. 2.
    Bernardi M, De Palma R, Trevisani F et al. (1986) Effects of a new loop diuretic (muzolimine) in cirrhosis with ascites: comparison with furosemide. Hepatology6: 400–405PubMedCrossRefGoogle Scholar
  3. 3.
    Better OS, Schrier RW (1983) Disturbed volume homeostasis in patients with cirrhosis of the liver. Kidney Int23: 303–311PubMedCrossRefGoogle Scholar
  4. 4.
    Bichet DG, van Putten VJ, Schrier RW (1982) Potential role of increased sympathetic activity in impaired sodium and water excretion in cirrhotis. N Engl J Med307: 1552–1557PubMedCrossRefGoogle Scholar
  5. 5.
    Billmann P, Schölmerich J, Wilms H (1983) Die Funktionsuntersuchung des peritoneo-venösen Shunt-systems. ROEFO138: 288–291CrossRefGoogle Scholar
  6. 6.
    Billmann P, Volk BA, Schölmerich J, Hasler K, Wilms H (1986) Lokale Lysetherapie bei thrombotischen Komplikationen des peritoneo-venösen Shunts. Z Gastroenterol24: 426–429PubMedGoogle Scholar
  7. 7.
    Blendis LM, Harrison JE, Russell DM, Miller C, Taylor BR, Greig PD, Langer B (1986) Effects of peritoneovenous shunting on body composition. Gastroenterology90: 127–134PubMedGoogle Scholar
  8. 8.
    Bloom D, McCalden TA, Rosendorff C (1975) Effects of jaundice plasma on vascular sensitivity to noradrenalin. Kidney Int8: 149–157PubMedCrossRefGoogle Scholar
  9. 9.
    de Bold AJ (1985) Atrial natriuretic factor. A hormone produced by the heart. Science230: 767–770PubMedCrossRefGoogle Scholar
  10. 10.
    Bories P, Compean DG, Michel H et al. (1986) The treatment of refractory ascites by the LeVeen shunt. A multi-centre controlled trial (57 patients). J Hepatology3: 212–218CrossRefGoogle Scholar
  11. 11.
    Burmeister P, Schölmerich J, Diener W, Gerok W (1986) Renin, aldosterone, and arginine vasopressin in patients with liver cirrhosis - the influence of ascites retransfusion. Eur J Clin Invest16: 117–123PubMedCrossRefGoogle Scholar
  12. 12.
    Decaux G, Mols P, Cauchie P, Flamion B, Delwiche F (1986) Treatment of hyponatremic cirrhosis with ascites resistant to diuretics by urea. Nephron44: 337–343PubMedCrossRefGoogle Scholar
  13. 13.
    Descos L, Gauthier A, Levy VG et al. (1983) Comparison of six treatments of ascites in patients with liver cirrhosis. A clinical trial. Hepatogastroenterol30: 15–20Google Scholar
  14. 14.
    Epstein M, Berk DP, Hollenberg NK, Adams DF, Chalmers TC, Abrams HL, Merrill JP (1970) Renal failure in the patient with cirrhosis. The role of active vasoconstriction. Am J Med49: 175–185PubMedCrossRefGoogle Scholar
  15. 15.
    Epstein M (1982) Peritoneovenous shunt in the management of ascites and the hepatorenal syndrome. Gastroenterology82: 790–799PubMedGoogle Scholar
  16. 16.
    Epstein M (1983) Renal sodium handling in cirrhosis. In: Epstein M (ed) The kidney in liver disease. Elsevier, New York, pp 25–53Google Scholar
  17. 17.
    Epstein M, Larios O, Johnson G (1985) Effects of water immersion on plasma cate-cholamines in decompensated cirrhosis. Implications for deranged sodium and water homeostasis. Miner Electrolyte Metab11: 25–34PubMedGoogle Scholar
  18. 18.
    Epstein M (1986) Renal prostaglandins and the control of renal function inliver disease. Am J Med80 [Suppl 1 A]: 46–55PubMedCrossRefGoogle Scholar
  19. 19.
    Fine LG, Sakhrani LM (1983) Toward a physiological definition of the hepatorenal syndrome. In: Epstein M (ed) The kidney in liver disease. Elsevier, New York, pp 107–117Google Scholar
  20. 20.
    Fogel MR, Sawhney VK, Neal EA, Miller RG, Knauer CM, Gregory PB (1981) Diuresis in the ascitic patient: a randomized controlled trial of three regimens. J Clin Gastroenterol 3 [Suppl 1]: 73 - 80PubMedCrossRefGoogle Scholar
  21. 21.
    Gauthier A, Levy VG, Quinton A et al. (1986) Salt or no salt in the treatment of cirrhotic ascites: a randomized study. Gut27: 705–709PubMedCrossRefGoogle Scholar
  22. 22.
    Gerbes AL, Arendt R, Wernze H, Riedel A, Xie Y, Liebermeister R, Paumgartner G (1986) Atrialer natriuretischer Faktor (ANF), Noradrenalin und Natriumausscheidung nach Wasserimmersion bei Patienten mit Leberzirrhose. Z Gastroenterol24: 38–39Google Scholar
  23. 23.
    Gerok W (1986) Biotransformation von Diuretika bei Leberkrankheiten. In: Knauf H, Mutschier E (Hrsg) Diuretika. Prinzipien der klinischen Anwendung. Urban amp; Schwarzenberg, München, S 73–92Google Scholar
  24. 24.
    Greig PD, Blendis LM, Langer B, Taylor BR, Colapinto RF (1981) Renal and hemody-namic effects of the peritonevenous shunt. II. Long-term effects. Gastroenterology80: 119–125PubMedGoogle Scholar
  25. 25.
    Häussinger D, Kaiser S, Stehle T, Gerok W (1986) Liver carbonic anhydrase and urea synthesis. The effect of diuretics. Biochem Pharmacol35: 3317–3322PubMedCrossRefGoogle Scholar
  26. 26.
    Heinrich F, Loew D, Dycka J (1983) Repeated-dose, double-blind comparative trial of muzolimine-spironolactone, furosemide-spironolactone, and placebo-spironolactone. Clin Nephrol19 [Suppl 1]: 69–75Google Scholar
  27. 27.
    Herzog P, Walther C, Holtermüller KH (1987) Natriumgehalt flüssiger Antacidum- Präparate. Dtsch Med Wochenschr112: 302–304PubMedCrossRefGoogle Scholar
  28. 28.
    Huber M, Kästner S, Schölmerich J, Gerok W, Keppler D (1989) Analysis of leucotrienes in human urine: Enhanced excretion in patients with liver cirrhosis and hepatorenal syndrome. Eur J Clin Invest19: 53–60PubMedGoogle Scholar
  29. 29.
    Iwatsuki S, Popovtzer MM, Corman JL, Ishikawa M, Putnam CW, Katz FH, Starzl TE (1973) Recovery from “hepatorenal syndrome” after orthotopic liver transplantation. N Engl J Med289: 1155–1159PubMedCrossRefGoogle Scholar
  30. 30.
    Jüngst D, Gerbes AL, Martin R, Paumgartner G (1986) Value of ascitic lipids in the differentiation between cirrhotic and malignant ascites. Hepatology6: 239–243PubMedCrossRefGoogle Scholar
  31. 31.
    Kanel GC, Peters RL (1984) Glomerular tubular reflux — a morphologic renal lesion associated with the hepatorenal syndrome. Hepatology4: 242–246PubMedCrossRefGoogle Scholar
  32. 32.
    Kao HW, Rakov NE, Savage E, Reynolds TB (1985) The effect of large volume paracentesis on plasma volume — a cause of hypovolemia? Hepatology5: 403–407PubMedCrossRefGoogle Scholar
  33. 33.
    Keppler D, Hagmann W, Rapp S, Denzlinger C, Koch HK (1985) The relation of leukotrienes to liver injury. Hepatology5: 883–891PubMedCrossRefGoogle Scholar
  34. 34.
    Keller E, Hoppe-Seyler G, Mumm R, Schollmeyer P (1981) Influence of hepatic cirrhosis and end-stage renal disease on pharmacokinetics and pharmacodynamics of furosemide. Eur J Clin Pharmacol20: 27–33PubMedCrossRefGoogle Scholar
  35. 35.
    Kinney MJ, Schneider A, Wapnick S, Grosberg S, LeVeen H (1979) The “hepatorenal” syndrome and refractory ascites: successful therapy with the Le-Veen-type peritoneal- venous shunt and valve. Nephron23: 228–232PubMedCrossRefGoogle Scholar
  36. 36.
    Knauf H, Mutschier E (1986) Wirkprofil von Diuretika. In: Knauf H, Mutschier E (Hrsg) Diuretika. Prinzipien der klinischen Anwendung. Urban amp; Schwarzenberg, München, S 93–111Google Scholar
  37. 37.
    Knauf H, Schollmeyer P, Gerok W (1986) Diuretika bei Nierenerkrankungen sowie Leberzirrhose mit Aszites. In: Knauf H, Mutschier E (Hrsg) Diuretika. Prinzipien der klinischen Anwendung. Urban amp; Schwarzenberg, München, S 141–160Google Scholar
  38. 38.
    Knauf H, Missmahl M, Schölmerich J, Gerok W, Mutschier E (1987) Altered kinetics of etozolin and its active metabolite ozolinone in hepatitis and hepatic cirrhosis with ascites. Drug Res 37: 1385–1388Google Scholar
  39. 39.
    Koppel MH, Coburn JW, Mims MM, Golstein H, Boyle JD, Rubini ME (1969) Transplantation of cadaveric kidneys from patients with hepatorenal syndrome. Evidence for the functional nature of renal failure in advanced liver disease. N Engl J Med280: 1367–1371PubMedCrossRefGoogle Scholar
  40. 40.
    Levy VG, Pauleau N, Opolon P, Caroli J (1975) Treatment of ascites by reinfusion of concentrated peritoneal fluid - review of 318 procedures in 210 patients. Postgr Med J51: 564–566CrossRefGoogle Scholar
  41. 41.
    Linas SL, Anderson RJ, Miller PD, Schrier RW (1983) The rational use of diuretics in cirrhosis. In: Epstein M (ed) The kidney in liver disease. Elsevier, New York, pp 555–567Google Scholar
  42. 42.
    Medina JF, Prieto J, Guarner F, Quiroga J, Milazzo A (1986) Effect of spironolactone on renal prostaglandin excretion in patients with liver cirrhosis and ascites. J Hepatol 3: 206–211PubMedCrossRefGoogle Scholar
  43. 43.
    Mutschier E (1986) Diuretika. Arzneimitteltherapie4: 183–190Google Scholar
  44. 44.
    Papper S (1983) Hepatorenal syndrome. In: Epstein M (ed) The kidney in liver disease. Elsevier, New York, pp 87–106Google Scholar
  45. 45.
    Pariente EA, Bataille C, Bercoff E, Lebrec D (1985) Acute effects of Captopril on systemic and renal hemodynamics and on renal function in cirrhotic patients with ascites. Gastroenterology 88: 1255–1259PubMedGoogle Scholar
  46. 46.
    Pavlow M (1883) The antitoxin functions of the liver. Lancet2: 1092–1093Google Scholar
  47. 47.
    Perez-Ayuso RM, Arroyo V, Planas R et al. (1983) Randomized comparative study of efficacy of furosemide versus spironolactone in non-azotemic cirrhosis with ascites. Relationship between the diuretic response and the activity of the renin-aldosterone system. Gastroenterology 84: 961–968PubMedGoogle Scholar
  48. 48.
    Pinzani M, Daskalopoulos G, Laffi G, Gentilini P, Zipser RD (1987) Altered furosemide pharmacokinetics on chronic alcoholic liver disease with ascites contributes to diuretic resistance. Gastroenterology 92: 294–296PubMedGoogle Scholar
  49. 49.
    Pockros PJ, Reynolds TB (1986) Rapid diuresis in patients with ascites from chronic liver disease: the importance of peripheral edema. Gastroenterology90: 1827–1833PubMedGoogle Scholar
  50. 50.
    Qazi R, Savlov ED (1982) Peritoneovenous shunt for palliation of malignant ascites. Cancer 49: 600–602PubMedCrossRefGoogle Scholar
  51. 51.
    Quintero E, Gines P, Arroyo V et al. (1985) Paracentesis versus diuretics in the treatment of cirrhotics with tense ascites. Lancet1: 611–612PubMedCrossRefGoogle Scholar
  52. 51 a.
    Runyon BA, Canawati HN, Akriviadis EA (1988) Optimization of ascitic fluid culture technique. Gastroenterology 95: 1351–1353PubMedGoogle Scholar
  53. 52.
    Schölmerich J, Volk BA, Röttgen E, Ehlers S, Gerok W (1984) Fibronectin concentration in ascites differentiates between malignant and nonmalignant ascites. Gastroenterology87: 1160–1164PubMedGoogle Scholar
  54. 53.
    Schölmerich J, Gerok W (1985) Diuretikatherapie bei Leberzirrhose mit Aszites. Therapiewoche35: 2185–2200Google Scholar
  55. 54.
    Schölmerich J, Diener W, Röttgen E, Maier KP, Costabel U, Gerok W (1985) Die extrakorporale Ascites-Reinfusion zur raschen Ascites-Elimination bei gastroenterolo-gischen Notfallpatienten. Intensivmedizin22: 308–314Google Scholar
  56. 55.
    Schölmerich J, Volk BA, Köttgen E, Hasler C, Wilms H, Billmann P, Gerok W (1985) Ascites — neue Aspekte zur Pathophysiologic, Diagnostik und Therapie. Dtsch Med Wochenschr110: 512–518PubMedCrossRefGoogle Scholar
  57. 56.
    Schölmerich J (1986) Hepatorenales Syndrom. In: Deutsch E, Blume W, Kleinberger G, Ritz R, Schuster HP (Hrsg) Akutes Nierenversagen und extrakorporale Therapieverfahren. Schattauer, Stuttgart, S 99 - 117Google Scholar
  58. 57.
    Schölmerich J (1987) Diagnostik und Therapie des Nierenversagens bei Leberzirrhose. Med Welt38: 1–7Google Scholar
  59. 58.
    Schölmerich J (1987) Diagnostik und Therapie des Ascites. Internist28: 448–458PubMedGoogle Scholar
  60. 59.
    Schölmerich J, Wenk E, Leser HG, Knauf H, Gerok W (1987) Xipamide in the treatment of cirrhotic ascites - results of two initial studies. Gastroenterology92: 1771Google Scholar
  61. 60.
    Schölmerich J, Zimmermann U, Köttgen E, Volk BA, Ehlers S, Gerok W (1987) Proteases and antiproteases related to the coagulation system in plasma and ascites. An approach to differentiate between malignant and cirrhotic ascites. Klin Wochenschr65: 634–638PubMedCrossRefGoogle Scholar
  62. 61.
    Schölmerich J, Zimmermann U, Köttgen E, Volk BA, Hasler C, Diener W, Gerok W (1987) Proteases and antiproteases related to the coagulation in plasma and ascites. The influence of dexamethasone. Klin Wochenschr65: 639–642PubMedCrossRefGoogle Scholar
  63. 61a.
    Schölmerich J, Zimmermann U, Köttgen et al. (1988) Proteases and antiproteases related to the coagulation system in plasma and ascites. Prediction of coagulation disorder in ascites retransfusion. J Hepatol6: 359–363PubMedCrossRefGoogle Scholar
  64. 61b.
    Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodés J (1988) Peripheral vasodilatation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology8: 1151–1157PubMedCrossRefGoogle Scholar
  65. 62.
    Schroeder ET, Anderson GH, Smulyan H (1979) Effects of a portacaval or peritoneo- venous shunt on renin in the hepatorenal syndrome. Kidney Int15: 54–61PubMedCrossRefGoogle Scholar
  66. 63.
    Sellinger M, Haag K, Mielke G, Gerok W, Knauf H (1985) Akutes Nierenversagen und Tubulusnekrose bei Verschlußikterus. Effekt von Gallensäuren und Bilirubin an der Tubulusmembran des Menschen. Z Gastroenterol23: 503Google Scholar
  67. 64.
    Sherlock S, Senewiratne B, Scott A, Walker JG (1966) Complications of diuretic therapy in hepatic cirrhosis. Lancet1: 1049–1052PubMedCrossRefGoogle Scholar
  68. 65.
    Skorecki KL, Brenner BM (1982) Body fluid homeostasis in congestive heart failure and cirrhosis with ascites. Am J Med72: 323–338PubMedCrossRefGoogle Scholar
  69. 66.
    Solis-Herruzo JA, Garcia-Cabezudo J, Diaz-Rubio C et al. (1986) Urinary excretion of enzymes in cirrhotics with renal failure. J Hepatol3: 123–130PubMedCrossRefGoogle Scholar
  70. 67.
    Stassen WN, McCullough AJ (1985) Management of ascites. Sem Liver Dis5: 291–307CrossRefGoogle Scholar
  71. 68.
    Vaamonde CA (1983) Renal water handling in liver disease. In: Epstein M (ed) The kidney in liver disease. Elsevier, New York, pp 55–86Google Scholar
  72. 69.
    Vassalli JD, Hamilton J, Reich E (1976) Macrophage plasminogen activator: modulation of enzyme production by antiinflammatory steroids, mitotic inhibitors, and cyclicnucle-otides. Cell8: 271–281PubMedCrossRefGoogle Scholar
  73. 70.
    Volk BA, Schölmerich J, Wilms H, Hasler K, Köttgen E, Gerok W (1985) Treatment of refractory ascites by retransfusion and peritoneo venous shunting. Dig Surg2: 93–97CrossRefGoogle Scholar
  74. 71.
    Volk BA, Schölmerich J, Wilms H et al. (1985) Peritoneo-venöser Shunt in der Aszites-therapie: Komplikationen der Behandlung. Dtsch Med Wochenschr110: 1685–1691PubMedCrossRefGoogle Scholar
  75. 72.
    Wapnick S, Grosberg SJ, Evans MI (1979) Randomized prospective matched pair study comparing peritoneovenous shunt and conventional therapy in massive ascites. Br J Surg66: 667–670PubMedCrossRefGoogle Scholar
  76. 73.
    Wernze H, Spech HJ, Müller G (1978) Studies on the activity of the renin-angiotensin-al-dosterone system (RAAS) in patients with cirrhosis of the liver. Klin Wochenschr56: 389–397PubMedCrossRefGoogle Scholar
  77. 74.
    Wilkinson SP, Smith IK, Williams R (1979) Changes in plasma renin activity in cirrhosis: a reappraisal based on studies in 67 patients with low-renin cirrhosis. Hypertension1: 125–129PubMedGoogle Scholar
  78. 75.
    Wietholz H, Schölmerich J, Knauf H, Gerok W, Spahn H, Mutschier E (1984) Phar-makokinetik von Xipamid bei Nieren- und Lebererkrankungen. Verh Dtsch Ges Inn Med90: 1902–1904Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1989

Authors and Affiliations

  • J. Schölmerich

There are no affiliations available

Personalised recommendations